Strategy Therapy on Cancer Therapy-Related Cardiac Dysfunction
Status:
Recruiting
Trial end date:
2025-12-31
Target enrollment:
Participant gender:
Summary
The investigators use the cancer registration system of National Cheng Kung University
Hospital to timely screen and evaluate those patients having breast cancer or lymphoma to
enroll patients to participate in this clinical trial. The investigators planned an earlier
initiation of Sacubitril/Valsartan treatment on breast cancer and lymphoma patients before
the chemotherapy, and starting therapeutic intervention by Sacubitril/Valsartan once the
heart damage sign appeared via novel echocardiography. The investigators aim to assess the
protective and therapeutic benefit of cardioprotective drugs on the cardiotoxicity of
anti-cancer therapy.